Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by American Academy of Neurology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Academy of Neurology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs

4:14
 
Share
 

Manage episode 482847887 series 2383645
Content provided by American Academy of Neurology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Academy of Neurology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.

  continue reading

104 episodes

Artwork
iconShare
 
Manage episode 482847887 series 2383645
Content provided by American Academy of Neurology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Academy of Neurology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.

  continue reading

104 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play